Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2025)
Historic Long-Term Deferred Tax for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $25.0 million.
- Centessa Pharmaceuticals' Long-Term Deferred Tax fell 751.43% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year decrease of 751.43%. This contributed to the annual value of $26.6 million for FY2024, which is 1032.48% down from last year.
- As of Q3 2025, Centessa Pharmaceuticals' Long-Term Deferred Tax stood at $25.0 million, which was down 751.43% from $25.4 million recorded in Q2 2025.
- Centessa Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $29.6 million during Q4 2023, with a 5-year trough of $3.5 million in Q4 2022.
- Moreover, its 4-year median value for Long-Term Deferred Tax was $26.8 million (2023), whereas its average is $25.2 million.
- In the last 5 years, Centessa Pharmaceuticals' Long-Term Deferred Tax soared by 74416.29% in 2023 and then crashed by 1127.05% in 2025.
- Over the past 4 years, Centessa Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $3.5 million in 2022, then skyrocketed by 744.16% to $29.6 million in 2023, then decreased by 10.32% to $26.6 million in 2024, then decreased by 5.88% to $25.0 million in 2025.
- Its Long-Term Deferred Tax stands at $25.0 million for Q3 2025, versus $25.4 million for Q2 2025 and $26.4 million for Q1 2025.